Kynetyka Technologies Pty Ltd

Kynetyka Technologies Pty Ltd is an Australian medical device company headquartered in Adelaide. Kynetyka is developing and commercialising DVTect®, a unique, patented, point-of-care device designed to detect deep vein thrombosis (DVT) quickly and accurately. Kynetyka is led by a team of experienced professionals, supported by leading clinical and technology advisors. The executive team has collectively over 120 years of global experience in the medical, pharmaceutical, and technology development sectors. They have the skills and knowledge to expedite development and commercialise DVTect®, improving detection and diagnosis of DVT, enhancing patient outcomes, and ultimately saving lives. DVTect® combines software and sensor technology to detect DVT. It is portable, affordable, and simple to use. It is designed for use by healthcare professionals and also non- medically trained personnel. When a patient has a DVT in the leg, there is a measurable change in the calf muscle’s response to movement. The DVTect® sensor is attached to the leg, which is lightly tapped to cause movement in the muscle. The sensor captures the resulting 3D waveform data and transmits it to the DVTect® software, which analyses the signal to detect the presence of DVT. Results are displayed instantly on a smart device or computer. DVTect® is faster and easier to use than ultrasound devices. It has the potential to reduce unnecessary ultrasounds, avoid preventable deaths from pulmonary embolism, and the overuse of anticoagulants. Use of DVTect® could result in an estimated healthcare cost saving of over $4 billion per year in the USA and Australia. Currently in development, DVTect® is initially targeted for use in hospitals, including post-surgery wards, intensive care units, and emergency departments. Future expansion will introduce DVTect® into community settings including general practice/primary care, aged care, maternal health and regional and remote communities.